Establishing non-inferiority in treatment trials in psychiatry — guidelines from an Expert Consensus Meeting
暂无分享,去创建一个
T. Peters | D. Nutt | H. Wittchen | Y. Lecrubier | C. Allgulander | David J. Nutt | Timothy J. Peters | H. Wittchen | Yves Lecrubier | Christer Allgulander
[1] D. Nutt,et al. Development and validation of the Generalized Anxiety Disorder Inventory (GADI) , 2006, Journal of psychopharmacology.
[2] P. Gøtzsche. [Noninferiority and equivalence randomized trials: lessons and reservations--secondary publication]. , 2006, Ugeskrift for læger.
[3] D. Baldwin,et al. Escitalopram in the treatment of generalized anxiety disorder , 2005, Expert review of neurotherapeutics.
[4] A. Reynolds,et al. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. , 2003 .
[5] D. Sheehan,et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. , 2003, The American journal of psychiatry.
[6] Yi Tsong,et al. Some fundamental issues with non‐inferiority testing in active controlled trials , 2002, Statistics in medicine.
[7] C. Allgulander,et al. Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder , 2001, British Journal of Psychiatry.
[8] M. Pollack,et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. , 2001, The Journal of clinical psychiatry.
[9] A. Gelenberg,et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. , 2000, JAMA.
[10] D. Sheehan,et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. , 2000, The American journal of psychiatry.
[11] J. Davidson,et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. , 1999, The Journal of clinical psychiatry.